Plus Therapeutics enters $50M common stock purchase agreement with Lincoln Park Capital

PLUS THERAPEUTICS, INC.

Plus Therapeutics signed a purchase agreement with Lincoln Park Capital for up to $50 million of common stock over 36 months.
Lincoln Park commits to buy up to 300,000 shares per regular purchase (up to 500,000 at higher prices) at 97% of market price.
The company will pay a $500,000 initial commitment fee in cash or stock, plus $500,000 after reaching $25 million in sales.
Proceeds will fund working capital and a $17.3 million make-whole repayment to March 2025 warrant holders.
Issuance beyond 10,194,593 shares requires shareholder approval unless average sale price exceeds $0.3576.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.